Last updated on September 2018

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Brief description of study

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Clinical Study Identifier: NCT02704403

Contact Investigators or Research Sites near you

Start Over

Alice Roudot, PharmD

Florida Medical Clinic, PA
Zephyrhills, FL United States
  Connect »